Form 4: Arvinas Director Leslie Norwalk Receives Significant Equity Grants

Arvinas, Inc. Director Leslie V Norwalk was granted 16,025 restricted stock units and options to purchase 23,105 shares of common stock as part of her compensation.

Summary

• Leslie V Norwalk, a Director of Arvinas, Inc. (ARVN), reported changes in her beneficial ownership of company securities.
• On June 25, 2025, Ms. Norwalk was granted 16,025 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Arvinas' common stock upon settlement for no consideration.
• These RSUs are set to vest in full on the earlier of June 25, 2026, or the first meeting of the board of directors held after the next annual meeting of stockholders, contingent on Ms. Norwalk's continued service.
• Additionally, on June 25, 2025, Ms. Norwalk received an option award to purchase 23,105 shares of common stock at an exercise price of $7.8 per share.
• The shares underlying this option award will also vest in full on the earlier of June 25, 2026, or the first meeting of the board of directors held after the next annual meeting of stockholders, subject to her continued service.
• Following these transactions, Ms. Norwalk beneficially owns 26,045 shares of common stock directly and 23,105 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is positive as the grants align the director's interests with shareholders and represent a standard, expected form of compensation, indicating continued commitment from the director.

Positives

• The equity grants align the interests of Director Leslie V Norwalk with those of the shareholders, incentivizing long-term performance and value creation.
• The grants represent a form of compensation that ties the director's financial benefit directly to the company's stock performance.

Risks

• The vesting of both the RSUs and stock options is contingent upon Leslie V Norwalk's continued service with Arvinas, Inc., meaning the benefits are not guaranteed if her service terminates before the vesting date.

Future Outlook

The grants of RSUs and stock options are forward-looking, with vesting contingent on continued service until June 25, 2026, or the first board meeting after the next annual stockholders' meeting, aligning the director's future incentives with company performance.

Industry Context

The granting of equity awards to directors is a standard practice across industries, particularly in the biotechnology and pharmaceutical sectors where long-term development cycles necessitate strong alignment between leadership and shareholder interests. These grants serve as a common mechanism for executive and director compensation, aiming to retain talent and incentivize performance.

Comparison to Industry Standards

• The structure of these equity grants (RSUs and stock options with service-based vesting) is consistent with typical compensation packages for non-employee directors in the U.S. biotechnology industry.
• While specific comparable companies or projects are not detailed in this Form 4, the use of zero-cost RSUs and options with a defined exercise price is a common method to provide equity incentives, similar to practices at peer companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, though the specific grant sizes would vary based on company size, stage, and compensation philosophy.

Related Party Transactions

• The equity grants to Leslie V Norwalk, a director of Arvinas, Inc., constitute a related party transaction as they involve compensation from the company to an insider. This is a standard and disclosed form of director compensation.

Stakeholder Impact

• Shareholders: The grants are generally positive for shareholders as they align the director's financial incentives with the company's long-term performance and stock value.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The grants reinforce the compensation structure for key personnel, potentially aiding in retention and motivation.

Next Steps

• The RSUs and stock options are expected to vest in full on the earlier of June 25, 2026, or the first meeting of the board of directors of Arvinas, Inc. held after the following annual meeting of stockholders, subject to Leslie V Norwalk's continued service.

Key Dates

Keywords

Arvinas, ARVN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership